Ntaios George, Perlepe Kalliopi, Lambrou Dimitrios, Sirimarco Gaia, Strambo Davide, Eskandari Ashraf, Karagkiozi Efstathia, Vemmou Anastasia, Koroboki Eleni, Manios Efstathios, Makaritsis Konstantinos, Vemmos Konstantinos, Michel Patrik
Department of Internal Medicine School of Medicine Larissa University Hospital University of Thessaly Larissa Greece.
Stroke Center and Neurology Service Department of Clinical Neurosciences Centre Hospitalier Universitaire Vaudois and University of Lausanne Switzerland.
J Am Heart Assoc. 2019 Aug 6;8(15):e012858. doi: 10.1161/JAHA.119.012858. Epub 2019 Jul 31.
Background We aimed to assess the prevalence and degree of overlap of potential embolic sources (PES) in patients with embolic stroke of undetermined source (ESUS). Methods and Results In a pooled data set derived from 3 prospective stroke registries, patients were categorized in ≥1 groups according to the PES that was/were identified. We categorized PES as follows: atrial cardiopathy, atrial fibrillation diagnosed during follow-up, arterial disease, left ventricular disease, cardiac valvular disease, patent foramen ovale, and cancer. In 800 patients with ESUS (43.1% women; median age, 67.0 years), 3 most prevalent PES were left ventricular disease, arterial disease, and atrial cardiopathy, which were present in 54.4%, 48.5%, and 45.0% of patients, respectively. Most patients (65.5%) had >1 PES, whereas only 29.7% and 4.8% of patients had a single or no PES, respectively. In 31.1% of patients, there were ≥3 PES present. On average, each patient had 2 PES (median, 2). During a median follow-up of 3.7 years, stroke recurrence occurred in 101 (12.6%) of patients (23.3 recurrences per 100 patient-years). In multivariate analysis, the risk of stroke recurrence was higher in the atrial fibrillation group compared with other PES, but not statistically different between patients with 0 to 1, 2, or ≥3 PES. Conclusions There is major overlap of PES in patients with ESUS. This may possibly explain the negative results of the recent large randomized controlled trials of secondary prevention in patients with ESUS and offer a rationale for a randomized controlled trial of combination of anticoagulation and aspirin for the prevention of stroke recurrence in patients with ESUS. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02766205.
背景 我们旨在评估不明来源栓塞性卒中(ESUS)患者潜在栓塞源(PES)的患病率及重叠程度。方法与结果 在一个源自3个前瞻性卒中登记处的汇总数据集中,根据所识别的PES将患者分为≥1组。我们将PES分类如下:心房病变、随访期间诊断出的心房颤动、动脉疾病、左心室疾病、心脏瓣膜病、卵圆孔未闭和癌症。在800例ESUS患者中(43.1%为女性;中位年龄67.0岁),3种最常见的PES是左心室疾病、动脉疾病和心房病变,分别存在于54.4%、48.5%和45.0%的患者中。大多数患者(65.5%)有>1种PES,而仅有29.7%和4.8%的患者分别有1种或没有PES。31.1%的患者存在≥3种PES。平均而言,每位患者有2种PES(中位数为2)。在中位随访3.7年期间,101例(12.6%)患者发生了卒中复发(每100患者年23.3次复发)。在多变量分析中,与其他PES相比,心房颤动组卒中复发风险更高,但在有0至1种、2种或≥3种PES的患者之间无统计学差异。结论 ESUS患者中PES存在大量重叠。这可能解释了近期ESUS患者二级预防大型随机对照试验的阴性结果,并为抗凝与阿司匹林联合预防ESUS患者卒中复发的随机对照试验提供了理论依据。临床试验注册网址:http://www.clinicaltrials.gov。唯一标识符:NCT02766205。